x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012880
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Synip (C51G6) Rabbit mAb is produced by immunizing rabbits with a synthetic peptide corresponding to the sequence of human Synip. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | STXBP4 |
| UniProt No. | Q6ZWJ1 |
| Gene ID | 252983 |
| Gene Description | Insulin binds to and activates its receptor and initiates a signaling cascade that eventually induces the translocation of the Glut4 glucose transporter from its intracellular locations to the plasma membrane. Initiating this pathway facilitates glucose uptake in fat and skeletal muscle cells. Synip and Syntaxin 4 are two proteins thought to be involved in the recruitment of Glut4-containing vesicles to plasma membrane. Synip associates with Syntaxin 4 when insulin is absent. Insulin signaling triggers the dissociation of the two proteins and allows Syntaxin 4 to complex with VAMP2, which is essential for Glut4 translocation to plasma membrane. Overexpression of a dominant-negative form of Synip prevents Glut4 from translocating to plasma membrane in response to insulin stimulation. Synip together with Syntaxin 4, therefore, regulates Glut 4 transport to plasma membrane. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
